预约演示
更新于：2025-12-20
Rezafungin acetate
雷扎芬净
更新于：2025-12-20
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)申请上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、合格传染病产品 (美国)、孤儿药 (欧盟)、优先审评 (美国)、优先审评 (欧盟) |
登录后查看时间轴
结构/序列
分子式C65H88N8O19 |
InChIKeyMXMWJAPNUIKPGF-YOFVRWEXSA-N |
CAS号1631754-41-0 |
Sequence Code 14003067
关联
14
项与 雷扎芬净 相关的临床试验NCT06774144
Rezafungin Prophylaxis in Liver Transplant at High Risk for Invasive Fungal Infection
This is an interventional study to evaluate the efficacy of rezafungin, a new echinocandin, for the prevention of invasive fungal infections (IFIs) after liver transplantation. Patients who receive rezafungin will be compared to a similar group of patients who underwent liver transplantation in the preceding two years for the incidence of IFIs.
开始日期2025-10-15 |
申办/合作机构 |
NCT06985758
Phase IV, Open-label, Single Arm, Multicenter Trial to Evaluate Pharmacokinetic Parameters of Peritoneal Diffusion and Peritoneal Diffusion Activity.
Intra-abdominal candidiasis is the most frequent candidiasis infection after candidemia. The studies that have positioned echinocandins as the first therapeutic option in candidiasis have been carried out mainly in patients with candidemia. Peritoneal concentrations of caspofungin, micafungin and anidulafungin are clearly above the MICs of most Candida spp but are below the threshold for selection of resistant mutants, which has been argued by some researchers as a risk for the control of intra-abdominal infections with poor control of the focus and selection of resistant mutants, observed in Candida spp isolates at the peritoneal level in relation to isolates at the blood culture level.
Rezafungin, with its special pharmacokinetics, achieves higher tissue concentrations, including hepato-splenic and other abdominal organs, than the other echinocandins. Experimental studies have confirmed that the concentration of rezafungin at the level of the inflammatory focus in abdominal infections is higher than in the surrounding healthy tissue and higher than those achieved by micafungin. Finally, the biofilm activity of rezafungin is very high, clearly superior to fluconazole and possibly higher than that of other echinocandins.
Rezafungin, with its special pharmacokinetics, achieves higher tissue concentrations, including hepato-splenic and other abdominal organs, than the other echinocandins. Experimental studies have confirmed that the concentration of rezafungin at the level of the inflammatory focus in abdominal infections is higher than in the surrounding healthy tissue and higher than those achieved by micafungin. Finally, the biofilm activity of rezafungin is very high, clearly superior to fluconazole and possibly higher than that of other echinocandins.
开始日期2025-09-01 |
NCT06794554
A Phase 2, Multicentre, Open-label, Single Arm Study to Evaluate the Effectiveness and Safety of Rezafungin (as Acetate) in the Treatment of Chronic Pulmonary Aspergillosis (CPA) in Patients With Limited Treatment Options
The goal of this clinical trial is to to evaluate the drug rezafungin in the treatment of Chronic Pulmonary Aspergillosis (CPA) in male and female patients aged 18 years and over with limited treatment options.
The study aims to answer whether 6 months of rezafungin treatment is effective and safe in patients with chronic pulmonary aspergillosis with limited treatment options according to clinical and radiological response as measured by the St George's Respiratory Questionnaire, weight, and CT imaging.
Participants will:
* Be given the drug rezafungin every week for 6 months.
* Visit the clinic once a month for checkups and tests.
* Complete questionnaires on thier health and wellbeing.
The study aims to answer whether 6 months of rezafungin treatment is effective and safe in patients with chronic pulmonary aspergillosis with limited treatment options according to clinical and radiological response as measured by the St George's Respiratory Questionnaire, weight, and CT imaging.
Participants will:
* Be given the drug rezafungin every week for 6 months.
* Visit the clinic once a month for checkups and tests.
* Complete questionnaires on thier health and wellbeing.
开始日期2025-06-30 |
申办/合作机构 |
100 项与 雷扎芬净 相关的临床结果
登录后查看更多信息
100 项与 雷扎芬净 相关的转化医学
登录后查看更多信息
100 项与 雷扎芬净 相关的专利（医药）
登录后查看更多信息
113
项与 雷扎芬净 相关的文献（医药）2026-01-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Development of a rezafungin isolate verification panel and comparison of reference method to ThermoFisher Sensititre YeastOne panel MIC results
Article
作者: Koeth, Laura ; DiFranco-Fisher, Jeanna
Rezafungin is indicated for the treatment of adults with limited or no alternative treatment options for candidemia and invasive candidiasis. The development of a rezafungin isolate verification panel is described. A total of 35 Candida species isolates were chosen for initial testing and 30 isolates were selected for additional testing including C. albicans (n = 11), C. glabrata (n = 8), C. tropicalis (n = 7) and C. parapsilosis (n = 4). Modal MIC, range of results and categorical agreement results (based on an acceptable ±2 dilution from the modal MIC) were calculated. Both FDA STIC and CLSI breakpoints were applied to calculated categorical agreement. The replicate reference BMD (rBMD) MIC results spanned an average of 2.4-dilution range and were within ±1 dilution of the modal rBMD for 26/30 (86.7 %) isolates and within ±2 dilutions for all isolates (100 %). The final panel of isolates was used to compare rBMD MIC values with those generated using the Sensititre™ YeastOne™ panel. The correlation of YeastOne results to modal rBMD results was particularly good; 26 out of 30 isolates (86.7 %) were within ±1 dilution of the modal rBMD and 100 % were within ±2 dilutions. When categorical agreement was calculated using CLSI and FDA breakpoints, CLSI criteria performed better than FDA, albeit this was associated with a limited number of isolates with MIC results near the breakpoints. The availability of a curated verification panel with rezafungin modal MIC values will be a valuable resource for laboratories as they incorporate testing devices containing rezafungin into their yeast susceptibility testing paradigm.
2025-12-02·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Antifungal treatment strategies and their impact on resistance development in clinical settings
Review
作者: Van Rhijn, Norman ; White, P Lewis
Abstract:
Invasive fungal diseases, particularly among immunocompromised patients, represent a growing clinical challenge due to limited therapeutic options, diagnostic delays and escalating antifungal resistance. Fungal pathogens employ diverse resistance mechanisms, including genetic mutations of antifungal target enzymes, biofilm formation, efflux pump overexpression and reduced drug penetration, which compromise the efficacy of clinically available antifungal classes. This review explores antifungal treatment modalities and evaluates approaches to mitigate resistance development. Advanced diagnostics and therapeutic drug monitoring are pivotal for enabling timely, targeted therapies and personalizing treatment plans, thus minimizing reliance on broad-spectrum agents. New antifungal agents, such as rezafungin, olorofim and fosmanogepix, along with long-acting and advanced formulations plus combination regimens, show substantial promise for managing resistance and improving treatment outcomes. Additionally, the development of immunotherapies and antifungal vaccines offers new avenues for bolstering host defences against fungal pathogens. Addressing antifungal resistance demands a multifaceted ‘One Health’ approach that integrates robust diagnostics, antifungal stewardship (AFS), precision medicine and collaborative global efforts. By advancing drug formulations, enhancing diagnostic tools and implementing forward-thinking AFS practices, the healthcare community can better tackle the escalating burden of fungal infections and deliver improved patient outcomes.
2025-11-04·ASM Case Reports
Bad to the bone:
Candida (Candidozyma) auris
vertebral osteomyelitis treated with combination antifungal therapy followed by a novel long-acting echinocandin
Article
作者: Karaman, Boris A. ; Jenkins, Lauryn B. ; Ghannoum, Mahmoud A. ; Christian, Robbie L. ; Dousa, Khalid M.
ABSTRACT:
Background:
Candida auris
is an emerging multidrug-resistant yeast associated with healthcare-associated infections and high mortality. Vertebral osteomyelitis due to
Candida auris
is rare and challenging to treat due to limited data on antifungal bone penetration, prolonged treatment duration, and resistance to multiple antifungal classes. Long-acting agents such as rezafungin may offer promising outpatient options, though clinical experience remains limited.
Case Summary:
A 70-year-old male developed vertebral osteomyelitis/discitis at T3–T4 due to
Candida auris
, following multiple catheter-related bloodstream infections and
C. auris
candidemia. Initial treatment included dual antifungal therapy with liposomal amphotericin B and micafungin, selected based on
in vitro
susceptibility and preclinical synergy data. Therapy was complicated by severe electrolyte disturbances, requiring early discontinuation of amphotericin B. He transitioned to rezafungin and completed nearly 3 months of treatment at home, contributing to a total of 6 months of antifungal therapy in alignment with IDSA guidelines. Rezafungin was generally well tolerated, with only mild hypokalemia and episodic migraine-like symptoms. The patient achieved complete clinical recovery with the resolution of symptoms and normalization of inflammatory markers. No relapse was reported at the 6-month follow-up.
Conclusion:
This case highlights the complexity of managing invasive
Candida auris
osteomyelitis and underscores the utility of dual antifungal combination therapy to enhance efficacy and potentially prevent the development of resistance during the intensive phase of treatment. It also demonstrates the feasibility of using rezafungin as an option for long-term outpatient management. Given the limited clinical experience with combination therapy and rezafungin use, further data are needed to inform standardized treatment approaches.
202
项与 雷扎芬净 相关的新闻（医药）2025-12-18
DefenCath® demonstrated a 72% reduction in CRBSI and 70% reduction in hospitalizations secondary to CRBSIBERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced interim results for the Company’s ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care’s (USRC) use of DefenCath in adult hemodialysis patients with central venous catheters. CorMedix and USRC commenced the real-world evidence study upon outpatient commercial launch in July 2024. The study is designed to demonstrate the impact of the broad use of DefenCath in a real-world setting and prospectively assess rates of catheter-related bloodstream infections (CRBSI), as well as hospitalizations secondary to these infections. The study is designed to evaluate these data points for two years. Currently, more than 3,000 patients per month are receiving DefenCath on a routine basis at USRC facilities. CorMedix conducted a preliminary analysis of interim data for approximately 7,000 patients having received at least one dose of DefenCath in Year 1. Based on CorMedix’s analysis of the data available through September 30, 2025, compared to historical controls, use of DefenCath demonstrated an overall 72% reduction in CRBSI, and a 70% reduction in hospitalizations secondary to CRBSI. The Company believes this represents a meaningful reduction in risk in some of the most vulnerable patients as well as a significant source of cost savings to the healthcare community and payors. CMS spends more than $3 billion per year on costs associated with CRBSI in the ESRD patient population, as the average CRBSI-related hospitalization is estimated to cost approximately $63,000, and up to $110,000 per incident when accounting for other sequelae. Joseph Todisco, CEO of CorMedix, commented, “We are proud to announce interim results for our ongoing real-world evidence study with our partners at USRC. As one of our earliest outpatient customers, they have undertaken a significant effort in working with us on this important long-term study and ensuring patient access to DefenCath to prevent CRBSIs in hemodialysis patients at risk. We are now utilizing this data in discussions with customers and payers as we seek to broaden access to DefenCath and establish long-term reimbursement with Medicare Advantage.” Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer and Senior Vice President of Clinical Research and Medial Affairs at U.S. Renal Care stated that, “Our organization is deeply committed to advancing innovative therapies for our patients, and we are encouraged by the reduction in both serious infections and hospitalizations demonstrated in these preliminary results.” Paul T. Conway, Vice President and Chair of Policy for the American Association of Kidney Patients (AAKP) and a 48-year kidney patient stated, "Every kidney patient receiving hemodialysis understands the inherent and serious risks posed by catheter-related bloodstream infections, including repeat hospitalizations, exposure to powerful IV antibiotics, jeopardization of their transplant readiness and increased mortality. As the largest kidney patient organization in the nation, AAKP welcomes this new and compelling information about DefenCath and the opportunity to better protect highly vulnerable dialysis patients while simultaneously reducing infection incidents and hospital admissions. We believe this data also strongly reinforces the ongoing collaborations among healthcare providers, patient advocates and elected leaders committed to transforming status quo dialysis care by addressing the long-standing and unmet need for infection prevention measures that lower hospitalizations, reduce healthcare utilization and limit costs to taxpayers.” Secondary data points of missed treatment sessions, antibiotic utilization, and tPA utilization are also being assessed and may be announced with additional real-world evidence data in the future. CorMedix believes these data from this large, prospective, ongoing real-world study further underscore the LOCK-IT 100 clinical study results on which the FDA approval of DefenCath for ESRD hemodialysis patients was based. The Company expects to continue to discuss with customers and payors, such as Medicare Advantage plans, to emphasize the economic value of long-term infection prevention in these patients. About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline) for Injection, REZZAYO® (rezafungin), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate). CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements including, but not limited to statements regarding financial guidance, sales estimates, synergy estimates and timing, expectations and timing regarding clinical studies and development and expectations of CorMedix’s product pipeline, results of the real-world study, expectations regarding implementation and perceived benefits of CorMedix’s products. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact:Dan FerryManaging DirectorLifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576
临床结果临床3期上市批准并购
2025-12-10
作者：中华医学会呼吸病学分会
通信作者：叶枫，广州医科大学附属第一医院呼吸与危重症医学科 国家呼吸医学中心 国家呼吸系统疾病临床医学研究中心 广州呼吸健康研究院 广州国家实验室；瞿介明，上海交通大学医学院附属瑞金医院呼吸与危重症医学科 上海市呼吸感染性疾病应急防控与诊治重点实验室 上海交通大学医学院呼吸病研究所
引用本文：中华医学会呼吸病学分会. 侵袭性肺真菌病诊断与治疗指南（2025年版）[J]. 中华结核和呼吸杂志, 2025, 48(12): 1104-1126. DOI: 10.3760/cma.j.cn112147-20250819-00501.
摘要
为进一步规范我国侵袭性肺真菌病（IPFD），特别是非免疫抑制宿主IPFD（IPFDNIH）的诊治，提高广大医务工作者的诊治水平，中华医学会呼吸病学分会感染学组组织相关领域的专家，参考欧洲癌症研究与治疗组织和真菌研究小组教育与研究联合会（EORTC/MSGETC）等组织制订的相关指南和专家共识，结合国内外近年来的研究进展、我国的实际情况与诊治经验，广泛征求国内多学科专家的意见，对《肺真菌病诊断与治疗专家共识（2007年版）》进行了全面更新，本次更新采用综述与问题相结合的形式呈现，聚焦于诊断与治疗等方面的内容，对IPFD诊治中的重要问题提出了16条推荐意见，以供我国医务工作者借鉴与参考。
近年来，随着广谱抗菌药物、糖皮质激素、免疫抑制剂等药物的广泛使用，实体器官和异基因造血干细胞移植受者的增多，侵袭性肺真菌病（invasive pulmonary fungal disease，IPFD）的发病率和病死率不断上升。2022年，世界卫生组织（world health organization，WHO）首次发布了真菌重点病原体清单［1］，标志着侵袭性真菌病已成为全球关注的重大感染性疾病，而肺部是最常累及的器官［2, 3］。临床实践中发现慢性阻塞性肺疾病、糖尿病、重症病毒性肺炎等非免疫抑制宿主IPFD（IPFD in non-immu nosuppressed hosts，IPFDNIH）的发病率上升，但此类患者的临床特征和影像学缺乏特异性、血清学检查敏感度低，早期诊断困难，误诊、漏诊及病死率高。尽管国内外已有多部指南和专家共识，但欧洲癌症研究与治疗组织和真菌研究小组教育与研究联合会（EORTC/MSGETC）的侵袭性真菌病指南主要适用于免疫抑制宿主［4］；重症监护病房侵袭性真菌病（FUNDICU）共识聚焦于重症患者［5］。此外，分子生物学技术的迅速发展及新一代抗真菌药物的陆续上市，亦推动了诊治方案的更新。为此，中华医学会呼吸病学分会感染学组发起指南修订工作，在《肺真菌病诊断和治疗专家共识（2007年版）》的基础上，系统梳理了IPFD的危险因素、临床表现、诊断方法、治疗方案及临床关键问题，综合国内外最新流行病学与临床研究证据，提出循证意见，以期为该病的诊治提供参考与实践指引。
本指南适用于中国肺真菌病患者，目标用户为呼吸与危重症医学科、感染科、重症医学科等医护人员。指南工作组由呼吸、感染、神经、微生物、检验、药学等多学科专家组成，已在国际实践指南注册与透明化平台（practice guideline registration for transparency，PREPARE）上注册（注册号：PREPARE-2024CN1153）。
本指南通过专家会议讨论筛选临床问题，着重探索肺真菌病的诊断与治疗。检索PubMed、Embase、Cochrane Library及CNKI数据库，检索时间截至2025年6月21日，采用牛津循证医学中心（OCEBM 2011）分级［6］评价证据质量，分为5个级别：1级（高质量）、2和3级（中等质量）、4和5级（低质量）（表1），同时辅以定性研究质量评价——关键质量评估技能项目（critical appraisal skills program，CASP）清单评估研究可靠性。综合考虑证据质量、利弊平衡、患者偏好、干预措施的可行性与可及性，形成推荐意见。所有推荐意见需经指南专家组成员不少于75%表决通过，不对推荐强度予以区分，有分歧时采用德尔菲法修改，并重新投票以达成共识。
一、IPFD的流行病学
全球每年有约650万侵袭性真菌感染患者，导致380万全因死亡，其中250万与真菌感染直接相关［7］。不同危险因素人群的流行病学存在差异，虽然免疫抑制宿主易感，但免疫功能正常人群亦可发生，且发病年龄呈现年轻化趋势，值得关注［8］。常见的病原体为曲霉、毛霉、隐球菌和肺孢子菌。
侵袭性肺曲霉病（invasive pulmonary aspergillosis，IPA）在造血干细胞移植、慢性阻塞性肺疾病、重症病毒性肺炎患者中发病率分别为6.0%、2.1%~5.3%和12.3%~28.1%；病死率分别为30.0%~57.0%［9, 10］、43.0%~72.0%［11］和43.5%［12］。肺毛霉病相对少见，发病率在新型冠状病毒感染（corona virus disease 2019，COVID-19）大流行后增加，继发感染率约1.10%［13］。
我国肺隐球菌病患者中，免疫功能正常人群占比高达60.0%以上［14］，占同期呼吸科住院患者的2.4‰［15］。
既往肺孢子菌肺炎（pneumocystis jirovecii pneumonia，PJP，亦简称PCP）常见于获得性免疫缺陷综合征（acquired immune deficiency syndrome，AIDS）患者，但近年来发病率持续下降［16］，而非AIDS患者中发病率呈上升趋势。血管炎、非霍奇金淋巴瘤、血液系统恶性肿瘤化疗、嵌合抗原受体T细胞（chimeric antigen receptor t-cell，CAR-T）治疗、异基因造血干细胞及实体器官移植等患者，未进行预防性治疗情况下发病率高于4.5%［17］。
侵袭性念珠菌病以血流感染和腹腔感染为主，原发性肺部感染少见。地方性真菌病的流行有显著的地域性差异。组织胞浆菌病、球孢子菌病、副球孢子菌病等主要流行于北美。我国以马尔尼菲篮状菌病常见［18］，以往主要分布在西南地区，近期的流行病学显示已超出了原疫区，发病率3.3%［19］，病死率6.5%~33.3%［20］。
二、IPFD的危险因素
IPFD的危险因素包括了宿主因素和环境因素（表2）。免疫抑制宿主及ICU患者均是IPFD的高危人群［4, 5，21］。肺隐球菌病在国内更常见于免疫功能正常人群［14，22］。控制不良的糖尿病是肺毛霉病首要的危险因素，近年来，异基因造血干细胞移植受者等血液病患者继发毛霉病的例数逐渐增多［4，23, 24, 25］。CD4+T淋巴细胞减少是PCP的独立危险因素。基础疾病及相关治疗所致的免疫功能低下，导致非AIDS患者的IPFD发病率持续上升［17］。此外，生物制剂和靶向药物引发的免疫受损，增加了真菌感染的风险。
三、IPFD的临床和影像学特征
IPFD的临床表现及严重程度与机体免疫状态密切相关，IPFDNIH和免疫抑制宿主IPFD的临床和影像学特征存在一定差异（表3）。
IPA是最常见的肺丝状真菌病。非粒细胞缺乏症患者以气道侵袭为主，呼吸道症状突出，胸部CT常表现为沿支气管分布的气道病变。免疫抑制宿主以血管侵袭常见，发热等全身症状明显，典型影像学表现为肺结节伴“晕征”或“空气新月征”等［26, 27, 28, 29, 30, 31, 32］。肺毛霉病患者发生大咯血的风险高，胸部影像学表现为多发肺结节、楔形实变、空洞，在病程1~2周时可见“反晕征”［33, 34, 35］。
免疫功能正常的肺隐球菌病患者通常症状较轻或无症状，免疫抑制宿主可出现急性肺炎样症状，病变累及中枢神经系统则可伴头痛。胸部CT常显示多发肺结节或肿块；严重免疫抑制宿主则可见更多不规则肿块影和大面积实变影［36, 37, 38］。
非AIDS的免疫抑制宿主合并PCP时，以急性肺炎症状常见，易合并呼吸衰竭，可快速进展为重症。胸部CT常表现为快速进展的弥漫性磨玻璃影和结节影。
四、IPFD诊断的方法学（表4）
五、IPFD的分级诊断标准
IPFD诊断分为确诊、临床诊断和拟诊3个级别（表5）。
确诊（proven）：由针吸或活检所获无菌组织病理学、细胞病理学或直接镜检，可见真菌特有的形态，且伴有相关组织损伤的证据和（或）以下任何一项证据：（1）无菌术下取得的肺组织、胸腔积液或血液标本培养有真菌生长，但血液标本曲霉或青霉（马尔尼菲篮状菌除外）培养阳性时，需结合临床排除标本污染的可能；（2）血隐球菌荚膜多糖抗原阳性，且临床与影像符合肺隐球菌病特点；（3）肺组织、BALF或痰液用常规或免疫荧光染色方法发现肺孢子菌包囊或滋养体；（4）无菌新鲜组织的 PCR/mNGS/tNGS 检出真菌或经甲醛固定石蜡包埋的组织中可见霉菌或酵母菌结合 PCR/mNGS/tNGS 辅助诊断。
临床诊断（probable）：同时具备至少1项危险因素（表2）、1项临床特征（表3）及以下任何1项微生物学证据：（1）下呼吸道标本霉菌/隐球菌培养或镜检阳性；（2）外周血或BALF的PCR/mNGS/tNGS检出真菌（念珠菌除外）；（3）外周血曲霉抗原GM值>0.5；（4）肺泡灌洗液曲霉抗原GM值≥1.0。
拟诊（possible）：具备至少1项危险因素（表2）、1项临床特征（表3），但无微生物学证据。为了避免过度诊治，免疫功能正常的非重症患者建议在确诊和临床诊断后再启动抗真菌治疗，而异基因造血干细胞移植、实体器官移植、CAR-T治疗、血液肿瘤患者拟诊可启动治疗。
六、IPFD的常用治疗药物
IPFD常用的治疗药物包括多烯类、三唑类及棘白菌素类（表6）。临床用药时需结合其药代动力学（pharmacokinetics，PK）、药效学（pharmacodynamics，PD）特征以及患者的特殊病理生理状况合理选择［39］。两性霉素B脱氧胆酸盐（AmB-D）肾毒性高，两性霉素B脂质体（L-AmB）和两性霉素B胶状分散体（ABCD）肾毒性显著降低，在肝肾功能不全患者中通常无需调整剂量［40］。多数三唑类抗真菌药口服生物利用度良好，组织分布广泛，尤其是肺支气管组织中渗透率较高。伏立康唑、伊曲康唑主要通过细胞色素P450（CYP）酶代谢，并对该酶系统具有抑制作用；泊沙康唑主要经尿苷二磷酸葡萄糖醛酸转移酶1A4（UGT1A4）代谢；而艾沙康唑在肝脏中的代谢程度较低。氟康唑主要经肾脏排泄，需根据肌酐清除率调整剂量，艾沙康唑的排泄途径涉及肝肾两者，相对均衡。需注意的是，唑类抗真菌药物具有潜在的胚胎毒性，妊娠早期应禁用［41］。棘白菌素类药物包括卡泊芬净、米卡芬净和瑞扎芬净，蛋白结合率均大于90%。卡泊芬净、米卡芬净主要通过CYP酶代谢，瑞扎芬净药物相互作用风险较低，其代谢产物主要经胆汁排泄，仅少量经肾脏排出。棘白菌素类在肝肾功能受损患者中安全性相对较好，但妊娠期仍应慎用。老年患者常合并多种基础疾病，使用抗真菌药物时需特别关注肝肾功能变化对药物代谢产生的潜在影响。
七、常见IPFD药物治疗方案的选择（表7）
八、IPFD相关的感染后炎性反应综合征
感染后炎症反应综合征（postinfectious inflammatory response syndrome，PIIRS）是指健康状况良好的IPFDNIH患者，在接受有效抗真菌治疗期间，因免疫反应过度增强而出现临床症状加重和（或）影像学进展，但多次真菌培养阴性。HIV阳性的IPFD患者予高效联合抗逆转录病毒治疗后，随着免疫缺陷状态的改善，因炎症反应过度而导致的病情恶化，称为免疫重建炎症综合征（immune reconstitution inflammatory syndrome，IRIS）。IRIS可分为矛盾型和暴露型，矛盾型IRIS指在抗逆转录病毒治疗前已存在真菌感染，抗感染治疗后一度好转，但在免疫功能恢复时出现病情反复；暴露型IRIS则指潜伏性感染者在免疫功能迅速恢复过程中发生的炎症综合征。免疫功能抑制的HIV 阴性患者可出现IRIS样重建综合征（IRIS-like reconstitution syndrome），尤其是血液恶性肿瘤患者予伏立康唑治疗IPA时，在粒细胞严重缺乏后的恢复期［61, 62, 63］。PIIRS、IRIS及IRIS样重建综合征均属于排他性诊断，需排除原发病加重或复发、抗真菌治疗失败、其他病原体引起的机会性感染以及肿瘤等。目前这些综合征尚缺乏标准化的治疗方案，在继续积极抗真菌治疗的基础上，可考虑使用泼尼松/泼尼松龙 0.5~1.0 mg/kg或地塞米松 0.2~0.3 mg/kg及非类固醇类抗炎药物进行辅助治疗［22］。
九、IPFD的疗效评估
IPFD的疗效需要结合临床症状、体征、实验室检查及影像学结果进行综合评估。抗真菌治疗通常较抗细菌起效慢，有效者多在1~2 周后临床症状和体征才开始改善，此时可初步进行疗效评估；重症应动态评估。疗效评估结果分为治疗成功（完全缓解、部分缓解）和治疗失败（疾病稳定、疾病进展、死亡）［32，34］（表8）。
十、IPFD常见的诊疗问题
（一）IPA的预防和经验治疗指征
［推荐意见1］建议对异基因造血干细胞移植或肺移植、接受CAR-T治疗、严重粒缺及接受大剂量免疫抑制剂治疗的IPA高风险患者，进行至少3周的预防性抗真菌治疗，直至宿主免疫状态改善（证据等级：2）。
［推荐意见2］建议对持续粒细胞减少且经广谱抗菌药物治疗后仍反复发热的患者启动经验性抗真菌治疗，直至临床状况趋于稳定、相关微生物学和（或）影像学指标恢复正常（证据等级：2）
推荐理由：IPA在高危人群中的发生率和病死率均较高，预防性治疗有助于改善预后［64］。美国一项多中心前瞻性研究显示，1 173例肺移植受者中，12.0%发生了IPA，3个月全因病死率为21.7%［65］。严重粒细胞减少或异基因造血干细胞移植受者，侵袭性霉菌病的病死率高达40.0%~50.0%［66］。肺移植受者预防抗真菌治疗后，IPA的发生风险显著降低［67, 68］。多中心随机对照试验证实，严重粒细胞缺乏、异基因造血干细胞移植等高风险患者进行超过3周的预防性治疗，可显著降低侵袭性曲霉病的发生率和病死率［69, 70］。
粒细胞减少伴持续性发热是导致侵袭性真菌感染患者死亡的重要原因［71］，及时启动经验性抗真菌治疗有助于改善预后。一项荟萃分析发现，粒细胞减少伴持续发热的癌症患者经验性抗真菌治疗可降低75%的感染风险，但未能显著改善全因病死率［72］。Cheng等［73］开展的多中心前瞻性观察研究发现，274例粒细胞减少伴发热的血液肿瘤患者，进行经验抗真菌治疗的总体应答率为43.4%，临床症状得到改善，生存率亦有所提高。多项国际多中心随机对照试验证实，对此类患者予经验性抗真菌治疗至临床状况稳定、宿主因素改善，能有效减少侵袭性真菌感染的发生，提高患者生存率［71，74］。（二）支气管镜介入技术和局部治疗在IPA中的应用
［推荐意见3］建议临床疑似IPA，尤其是侵袭性气管支气管曲霉病（invasive tracheobronchial aspergillosis，ITBA）的患者，尽早行气管支气管镜检查以明确诊断。（证据等级：3）。
［推荐意见4］对于坏死物阻塞了气道的ITBA患者，可经支气管镜行局部清创治疗；合并大咯血时，可采用支气管镜下球囊封堵、支气管动脉栓塞等介入治疗技术（证据等级：4）。
［推荐意见5］雾化吸入多烯类抗真菌药物主要用于高危人群的预防性治疗、ITBA的联合治疗，以及无法进行全身系统性抗真菌的替代治疗（证据等级：3）。
推荐理由：支气管镜检查可直接观察气道黏膜有无充血、水肿、溃疡、结节、假膜等曲霉侵袭的典型表现，有助于早期诊断ITBA，降低病死率［75, 76］。通过支气管镜可开展灌洗、刷检、活检等操作获取BALF或病变组织进行涂片镜检、培养、GM试验、PCR及病理等检查，以明确病原（理）学诊断［77, 78, 79, 80］。
对于坏死物阻塞气道的ITBA，经支气管镜行电凝、冷冻、钳夹、球囊扩张及支架植入等局部介入治疗，可有效清除坏死组织，改善气道狭窄，是实现紧急气道廓清、纠正呼吸衰竭的重要手段［81, 82, 83, 84］。若合并大咯血且药物干预无效时，可经支气管镜球囊封堵或支气管动脉栓塞进行干预［85, 86］。
研究表明，粒细胞减少、急性髓性白血病、实体器官移植受者以及气管插管的危重症COVID-19患者，局部雾化吸入多烯类药物可有效降低继发IPA的风险以改善预后［87, 88, 89］。全身抗真菌治疗有禁忌证或无法耐受的患者，可雾化吸入多烯类药物AmB-D（5~12.5 mg/次，1~2次/d）或L-AmB（25 mg/次，1次/d）作为替代疗法［90, 91］。（三）重症、难治性或治疗失败的IPA治疗方案
［推荐意见6］推荐重症、难治性或治疗失败的IPA予三唑类联合棘白菌素类/多烯类或棘白菌素类联合多烯类进行治疗（证据等级：4）。
推荐理由：实体器官或造血干细胞移植后、伴粒缺的急性髓系白血病、慢性阻塞性肺疾病、重型和危重型COVID-19，以及播散性或三唑类耐药曲霉感染的患者，建议采用两种抗真菌药物联合治疗［87，89］。全身性抗曲霉药物联合治疗的原则是选择作用机制不同或区别于初始方案的药物［87］，疗程至少应持续至患者病情改善。现有研究表明，三唑类与棘白菌素类在动物模型中显示出协同抗真菌效应，联合应用可显著降低真菌负荷、减少肺损伤并改善预后［93, 94］。体外PK/PD结合体内PK数据的蒙特卡罗模型表明伏立康唑与两性霉素B联合呈浓度依赖性有效：两性霉素B低暴露联合伏立康唑高暴露时，两种药物具有协同作用；两性霉素B高暴露，而伏立康唑低暴露时，两种药物联合呈现拮抗作用［87，92］。此外，联合方案的制订需综合考虑宿主免疫、治疗时机（初始治疗还是挽救性治疗）、药物耐受性、病原菌耐药可能性以及是否合并肺外曲霉感染等多种因素。（四）隐球菌荚膜多糖抗原（CrAg）检测的临床价值
［推荐意见7］CrAg具有重要的诊断价值，阳性提示隐球菌感染，但不建议仅依据该结果作出临床决策（证据等级：4）。
推荐理由：肺隐球菌病患者血清CrAg的敏感度和特异度分别为82.5%和94.1%［95］；脑脊液CrAg检测对隐球菌性脑膜炎的诊断敏感度和特异度可达到98.8%和99.3%［96］。当肺隐球菌病灶直径<2 cm时，使用BALF进行检测可提高诊断效能［97］。CrAg检测与滴度监测可作为评估抗真菌疗效的参考指标之一［98］，但不建议仅依据该结果作出临床决策。因为死亡的隐球菌菌体仍会持续释放荚膜多糖抗原，而机体清除此类抗原的速度较为缓慢。即使予有效治疗数月，多次真菌涂片及培养结果转阴后，体液中的CrAg检测仍可能呈阳性，故抗原持续阳性或滴度升高并不一定代表治疗失败或复发［99］。（五）肺隐球菌病患者腰椎穿刺的指征
［推荐意见8］肺隐球菌病患者合并神经系统症状或体征、血清CrAg滴度高或存在免疫功能低下状态时，建议行腰椎穿刺检查（证据等级：3）。
推荐理由：隐球菌感染一旦累及中枢神经系统，预后较差、病死率显著升高。约15%~20%的肺隐球菌病患者可能进展为隐球菌性脑膜炎，早期进行腰椎穿刺并干预可将病死率从40%降至20%。一旦患者出现头痛、意识障碍等神经系统症状，无论其抗原滴度高低，均为腰椎穿刺的绝对指征［52，100］。血清CrAg高滴度是进行腰椎穿刺的指征，但目前尚无统一滴度数值作为标准［22］。非免疫抑制肺隐球菌病患者中枢神经系统播散的发生率约20%，而实体器官移植受者的发生率则高达30%，肺隐球菌病患者抗原滴度≥1∶64，中枢神经系统感染风险升高［101］。（六）对氟康唑耐药或治疗失败的肺隐球菌病的治疗方案
［推荐意见9］氟康唑耐药或治疗失败的肺隐球菌病推荐以下替代治疗：（1）重症患者：L-AmB 3~6 mg·kg-1·d-1联合5-FC 100 mg·kg-1·d-1诱导治疗4周，后续氟康唑800 mg/d或伏立康唑维持治疗（证据级别：2）。（2）轻症或无法耐受两性霉素B的患者：可选用伏立康唑、泊沙康唑（注射液或肠溶片）或艾沙康唑，疗程6~12月（证据级别：2）。（3）若L-AmB不可及，可考虑使用大剂量氟康唑800~1 200 mg/d联合5-FC（证据级别：3）。
推荐理由：肺隐球菌病在规范治疗后若病灶不吸收或持续进展，应首先排除有无合并肿瘤的可能性。氟康唑耐药的判断需结合临床治疗反应和体外药敏试验。IDSA指南（2010）及ECMM/ISHAM全球指南（2024）均推荐以两性霉素B为基础的联合治疗，研究显示其治愈率超过70%，显著优于单药治疗［22，52］。三唑类药物具有良好的组织穿透性与抗真菌活性，可作为轻症肺隐球菌病的有效替代选择。Wang等［102］对84株新型隐球菌菌株的研究显示，多数菌株对伏立康唑（MIC平均值：0.04 mg/L）和泊沙康唑（MIC平均值：0.12 mg/L）的MIC值较低，Fan等［103］研究结果类似。Sudan等［104］指出，通过高剂量氟康唑联合其他药物，可作为挽救性治疗策略之一。国外多中心研究表明，接受唑类药物治疗的肺隐球菌病患者1年生存率为94%；在118例患者中，有2例初始接受唑类治疗后改为两性霉素B［105］。（七）肺毛霉病的联合治疗方案及其他治疗
［推荐意见10］不推荐常规联合应用两种抗真菌药物治疗肺毛霉病，但重症感染或单药疗效不佳时可考虑联合治疗（证据级别：4）。
推荐理由：目前尚缺乏高质量随机对照研究证实联合治疗优于单药，故不推荐常规联合应用两种抗真菌药物治疗肺毛霉病［35，44，106, 107］。下述情况可考虑L-AmB联合三唑类药物：重症、播散性或快速进展的感染（如病变范围广泛、短期内病灶扩散、合并咯血或血管侵袭、侵犯纵隔等）；未控制的糖尿病酮症酸中毒；单药治疗失败或突破性感染、重度免疫抑制者；因药物毒性无法使用足量抗真菌药物。联合用药可能增加肝肾毒性及药物相互作用风险，需结合患者具体情况进行个体化决策，并密切监测药物相关不良反应［44］。抗真菌治疗的疗程应根据患者的免疫状态、临床症状、影像学吸收情况综合决定。建议感染控制后继续抗真菌治疗4~6周以巩固疗效［35，106］。此外，对于正在接受祛铁治疗的患者，建议暂停使用祛铁剂［108］。（八）手术治疗在肺毛霉病治疗中的地位
［推荐意见11］肺毛霉病的手术治疗应遵循“早期评估、个体化决策、多学科协作”的原则。对于局限性病变，应早期积极评估手术时机；多发病变或手术高风险患者则需在治疗过程中动态评估手术必要性与可行性（证据级别：4）。
推荐理由：肺毛霉病病死率高达50%，联合手术可显著降低病死率［109］。手术是治疗肺毛霉病的关键手段，术前抗真菌治疗有助于缩小病变范围，提高手术可行性，尤其在残留单发病灶时手术更为安全有效［44］。早期手术干预还可降低致死性大咯血风险，减少后续急诊手术需求［35］。即使双肺有多发病灶或存在大咯血风险的患者，切除主要病灶仍可降低病死率［110, 111］。手术前后均需积极抗真菌治疗［35］。术后评估为完全缓解的患者，推荐予艾沙康唑或泊沙康唑肠溶片口服维持治疗至少4~6周；部分缓解的患者，推荐继续予L-AmB治疗4~6周后，再予艾沙康唑或泊沙康唑肠溶片口服维持［44］。若病变累及纵隔或存在播散性感染，手术风险极高，需权衡利弊，优先选择药物保守治疗或联合支气管镜介入治疗［112］。（九）肺毛霉病支气管镜介入治疗的时机、方法和注意事项
［推荐意见12］临床诊断或确诊的肺毛霉病患者在有条件的情况下可考虑经支气管镜行局部抗真菌药物灌注治疗（证据等级：4）。
［推荐意见13］确诊的肺毛霉病患者在术前或无法手术时，有经验的团队可经支气管镜行局部清创治疗（证据等级：4）。
推荐理由：肺毛霉病诊断后需紧急医疗干预，无法手术者若仅依靠全身药物治疗，通常预后较差［35］。2023年一项多中心临床研究表明，经支气管镜局部灌注抗真菌药物的治疗有效率可达72.5%［113］，因此建议在条件允许时尽早开展。常用药物主要为AmB-D（1 mg/ml），根据靶病灶大小每次5~20 ml局部保留灌注治疗，一般每周一次，亦可借助导航或超声支气管镜定位靶病灶，进行精准灌注治疗［114］。
毛霉常累及支气管，形成白色黏稠新生物（肺毛霉菌丝体）阻塞支气管管腔，组织病理可见大量坏死组织及毛霉菌丝［115］。建议有经验的团队在患者全身麻醉下建立有效人工气道的基础上行支气管镜介入清创治疗，目标是通过活检钳钳除、冷冻探头冻取等方式清除镜下可见的菌丝体。对于出血风险较高的患者应预置封堵球囊，必要时可先行肺血管栓塞术［115, 116］。2023年一项多中心小样本临床研究发现该治疗方法有效率接近100%［115］。此外，积极的支气管镜介入治疗有助于缩小和局限化病灶，为后续手术创造机会或降低手术难度［117］。（十）棘白菌素类药物在PCP治疗中的地位
［推荐意见14］不推荐单独予棘白菌素类药物治疗PCP，合并呼吸衰竭或肾功能不全时，建议棘白菌素与SMX-TMP联合治疗。（证据等级：2）。
［推荐意见15］SMX-TMP初始治疗失败或不耐受、耐药时，可予棘白菌素联合其他二线药物进行替代治疗（证据等级：4）。
推荐理由：迄今为止尚无单独使用棘白菌素治疗PCP的有效性研究，故不推荐单独使用。小样本回顾性研究表明棘白菌素与SMX-TMP联合治疗可提高重症PCP合并呼吸衰竭患者的临床反应率［118］。病例报告提示肾功能受损患者可使用棘白菌素联合适当剂量SMX-TMP作为二线治疗［119］。SMX-TMP初始治疗失败或不耐受、耐药时，予卡泊芬净联合其他二线治疗药物联合治疗可能有效［120, 121］。
（十一）PCP患者使用糖皮质激素治疗的指征
［推荐意见16］PCP患者合并严重低氧血症时，建议早期使用低剂量糖皮质激素，无低氧血症者不建议使用（证据等级：2）。
推荐理由：抗肺孢子菌治疗2~3 d后，患者呼吸状况可能因机体对死亡病原体的炎症反应而恶化，早期使用糖皮质激素可有效控制炎症。严重低氧血症（PaO₂<60 mmHg）患者使用低剂量激素可显著缩短机械通气时间，降低病死率［122, 123］。低剂量激素与较低病死率相关，而高剂量可能增加死亡风险［124］。轻度低氧血症（PaO₂>75 mmHg）患者，早期使用激素并无明显临床获益［125］。
十一、少见IPFD
普通人群中少见IPFD的发病率较低，但特定高危人群中呈逐渐上升趋势，且不同地区及人群间的病原谱存在差异，具有一定的特殊性。其宿主因素、流行病学特征、临床表现、病原学诊断及治疗详见表9。
十二、展望
近二十年来，尽管我们对IPFD有了进一步的认识，但临床诊治过程中仍面临诸多挑战。未来亟待开展以下工作：（1）研发新型诊断技术及生物标志物以提升早期诊断率。（2）基于循证医学制订针对不同免疫状态人群的个体化治疗方案。（3）挖掘人工智能（artificial intelligence，AI）在早期筛查、精准诊断及优化治疗中的潜力。（4）研发新型抗真菌药物及免疫疗法以应对耐药菌的感染。（5）对IPFD患者进行系统、综合的管理以提高治愈率。总之，IPFD发病率高、早期诊断率低、致死致残率高，治疗周期长，医疗负担重，是重大肺部感染性疾病之一，深入了解其发病机制、规范临床诊治、促进早防、早诊、早治，对于提升整体诊疗水平、降低病死率至关重要。
顾问：钟南山（广州医科大学附属第一医院）
审稿专家（按姓氏拼音排序）：曹彬（中日友好医院）、贺蓓（北京大学第三医院）、黄怡（海军军医大学第一附属医院）、赖国祥（福建中医药大学附属第二人民医院）、瞿介明（上海交通大学医学院附属瑞金医院）、施毅（南京大学医学院附属金陵医院）、张天托（中山大学附属第三医院）
负责人：叶枫（广州医科大学附属第一医院）、瞿介明（上海交通大学医学院附属瑞金医院）
参与撰写的专家组成员（按姓氏拼音排序）：范红（四川大学华西医院）、佘丹阳（解放军总医院呼吸与危重症医学部）、李玉苹（温州医科大学附属第一医院）、李征途（广州医科大学附属第一医院）、刘智博（中日友好医院）、鲁炳怀（中日友好医院）、牟向东（清华大学附属北京清华长庚医院）、彭福华（中山大学附属第三医院）、沈宁（北京大学第三医院）、苏欣（南京大学医学院附属鼓楼医院）、孙禾（同济大学附属东方医院）、孙文逵（南京医科大学第一附属医院）、叶枫（广州医科大学附属第一医院）、文文（联勤保障部队第九〇〇医院）、徐金富（同济大学附属同济医院）、张静（复旦大学附属中山医院）、张菁（复旦大学附属华山医院）、张巧（重庆松山医院）、张建全（中山大学附属第八医院）、周华（浙江大学医学院附属第二医院）、周敏（上海交通大学医学院附属瑞金医院）、朱利平（复旦大学附属华山医院）、朱迎钢（复旦大学附属华东医院）、卓超（广州医科大学附属第一医院）
参与讨论与投票专家组成员（按姓氏拼音排序）：常德（解放军总医院呼吸与危重症医学部）、陈愉（中国医科大学附属盛京医院）、陈一强（广西医科大学第一附属医院）、程齐俭（上海交通大学医学院附属瑞金医院）、程伟（四川大学华西医院）、冯泗州（中国医学科学院血液病医院）、范红（四川大学华西医院）、牟向东（清华大学附属北京清华长庚医院）、黄怡（海军军医大学第一附属医院）、姜淑娟（山东第一医科大学附属省立医院）、揭志军（复旦大学附属上海市第五人民医院）、李华茵（复旦大学附属中山医院）、李海潮（首都医科大学附属北京朝阳医院）、李园园（中南大学湘雅医院）、李玉苹（温州医科大学附属第一医院）、李征途（广州医科大学附属第一医院）、刘琳（贵州省人民医院）、刘学东（青岛市市立医院）、刘漪（昆明市第二人民医院）、刘智博（中日友好医院）、陆海雯（上海市肺科医院）、苏欣（南京大学医学院附属鼓楼医院）、苏振中（吉林大学第二医院）、孙禾（同济大学附属东方医院）、孙文逵（南京医科大学第一附属医院）、佘丹阳（解放军总医院呼吸与危重症医学部）、沈宁（北京大学第三医院）、田欣伦（中国医学科学院北京协和医院）、瞿介明（上海交通大学医学院附属瑞金医院）、王红民（郑州大学第一附属医院）、王辉（北京大学人民医院）、王凌伟（深圳市人民医院）、文文（联勤保障部队第九〇〇医院）、吴琦（天津医科大学总医院）、徐峰（浙江大学医学院附属二院）、徐金富（同济大学附属同济医院）、徐礼裕（福建医科大学附属福州市第一医院）、颜伏归（首都医科大学附属北京友谊医院）、叶枫（广州医科大学附属第一医院）、张建全（中山大学附属第八医院）、张静（复旦大学附属中山医院）、张巧（重庆松山医院）、张天托（中山大学附属第三医院）、张伟（江西省人民医院）、赵洪文（中国医科大学附属第一医院）、周华（浙江大学医学院附属第二医院）、周琼（华中科技大学同济医学院附属协和医院）、卓超（广州医科大学附属第一医院）、朱迎钢（复旦大学附属华东医院）
方法学专家和文献质量评价组：夏君[宁波诺丁汉大学GRADE 中心，中国临床实践指南联盟（GUIDANCE)]，江梅（广州医科大学附属第一医院）
写作组秘书：李少强、陈钊铭、苏玉天、李永明、陈悟殊（广州医科大学附属第一医院）；胡蔚萍（复旦大学附属中山医院）
参考文献（略）
点击页面左下角“阅读原文”，加入读者俱乐部下载全文
2025-12-04
Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review
抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述
Konstantinos Alexakis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771,
2
To be or not to be: the non-antimicrobial properties of common antimicrobials
生存还是毁灭：常见抗菌药物的非抗菌特性
Shivakumar Narayanan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783,
SYSTEMATIC REVIEWS（系统综述）
3
Antibiotic-induced Bartter-like syndrome: a systematic review
抗生素诱发的巴特综合征样表现：系统综述
Megha Priyadarshi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791,
4
Liposomal amphotericin B prophylaxis in paediatrics: a systematic review
两性霉素B脂质体预防性用药在儿科中的应用：系统综述
Emma V Thorley and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802,
ORIGINAL RESEARCH（论著）
5
Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study
婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究
Sarah F Hak and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812,
6
Plasmodium falciparum isolates: ex vivo drug response
恶性疟原虫分离株：体外药物反应
Edem Adika and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822,
7
Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia
低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827,
8
Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England
探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法
Ming Xuan Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836,
9
Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study
新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究
Yulia Butscheid and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848,
10
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy
意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析
Alessandro Cozzi-Lepri and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859,
11
Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model
基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型
Diego Vera-Yunca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868,
12
Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine
线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关
J R Macdonald and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877,
13
Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium
米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性
Kay Htaik and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884,
14
Early use of the novel antifungal rezafungin: a case series and literature review
新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述
H C Davidson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892,
15
Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach
基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量
Gisela Myrian de Lima Leite Dalla Rosa and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901,
16
Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade
过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关
Aliya El Nagar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906,
17
An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections
一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响
Mariagrazia Ciardo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914,
18
Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients
利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估
Xiaoping Shi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925,
19
Rapid susceptibility testing on urine for antimicrobial stewardship in general practice
全科实践中的尿液快速药敏试验助力抗菌药物管理
Patrick D J Sturm and Tanja Schülin
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932,
20
Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains
利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941,
21
In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains
新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性
Marie L G Attwood and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946,
22
Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions
中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性
Nadiia Mosiichuk and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950,
23
Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China
中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征
Zeqiang Zhan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963,
24
High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study
根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集
Zhengyu Luo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971,
25
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus
抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响
Aliona S Rosca and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979,
26
Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study
肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究
Lijuan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987,
27
Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875
多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征
Jonathan Koong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992,
28
Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum
改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较
Doris Hillemann and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996,
29
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations
由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转
Paschalis Paranos and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006,
30
Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France
瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构
Sofie M Edslev and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015,
31
Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections
抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估
Nischal Ranganath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024,
32
Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control
肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法
Ana Beatriz Gonçalves and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031,
33
Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori
抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性
Paweł Krzyżek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043,
34
A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro
生殖支原体体外诱导产生的新型阿奇霉素耐药突变
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050,
RESEARCH LETTERS（研究信函）
35
Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations
婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度
Jeffrey Harrington and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053,
36
Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis
两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法
Natacha Mrozek and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056,
37
Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis?
头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？
Alexandra Morin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058,
LETTER TO THE EDITOR（致编辑的信）
38
Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint
单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点
Miguel Villamarín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 8
抗菌化疗杂志 80卷 8期
https://academic.oup.com/jac/issue
Review(综述)
1
World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’
世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇”
Vazhayil Hari Krishnaprasad and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069
Original Research(论著)
2
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023)
氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结
Helio S Sader and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079
3
High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid
利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究
Hitoshi Kawasuji and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091
4
Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium
缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析
Yukitaka Hayashi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099
5
Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial
为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验
Nusrat Shafiq and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108
6
An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy
用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型
Cole McGrath and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116
7
Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa
黏液型铜绿假单胞菌纸片扩散法的优化与改进
Aixin Wang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125
8
HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022
乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查
Christine Watera and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134
9
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women
与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究
Sharana Mahomed and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144
10
Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study
接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究
Javier García-Abellán and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157
11
Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model
慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究
Midas B Mulder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168
12
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据
Roberta Gagliardini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178
13
Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial
病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验
Hsin-Yun Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186
14
Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia
青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究
Pernilla Kihlberg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193
15
Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202
16
Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway
齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌
Yun-Dan Zheng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213
17
Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study
阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究
Tom C Zwart and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225
18
48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial
HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析
Elisa de Lazzari and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233
19
The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time
多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响
Trenton Honda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240
20
Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales
一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估
Christian Moguet and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246
21
Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes
粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究
Matteo Rinaldi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256
22
Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus
靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染
Robin H G A van den Biggelaar and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268
23
Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm
基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279
24
Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy
意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件
Andrea Brenciani and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284
25
Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022
2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征
Corentin Poignon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294
26
Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections
具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁
Ye Jin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304
27
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性
Simon E Koele and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313
28
Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study
头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究
Dimitrios Basoulis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322
Research Letters(研究信件)
29
Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring
达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告
Carlo Pallotto and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324
30
A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs
韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174）
Hyeonwoo Cho and Kun Taek Park
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326
31
Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report
时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告
Layla Pagnucco and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330
32
Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48
土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征
Astrid Rasmussen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331
Letters to the Editor(致编辑的信)
33
Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital
述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究
Jianjun Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332
34
Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response
产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复
Gulhadiye Avcu
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333
Corrections(更正)
35
Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD)
更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334
36
Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs
更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335
37
Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics
更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2
抗菌化疗杂志 80卷 增刊2期
https://academic.oup.com/jac/issue
SUPPLEMENT (补充)
CANWARD 2007-23
加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告
Foreword(前言)
1
The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection
加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集
James C Hurley and Jean-Yves Madec
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1
Supplement Papers(补充论文)
2
Seventeen years of the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究17年（2007-2023年）
George G Zhanel and Heather J Adam
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4
3
Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14
4
Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23)
来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023）
George G Zhanel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26
5
Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023）
Anissa Brahami and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34
6
Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23)
加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23）
Heather J Adam and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44
7
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23
加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023
Philippe Lagacé-Wiens and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53
8
Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23)
加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23）
Laura F Mataseje and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61
9
Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23)
加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23）
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71
10
Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23)
加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果
Andrew Walkty and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82
Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期
https://academic.oup.com/jac/issue
VIEWPOINT（观点）
1
Classifying patients with invasive fungal disease: towards a unified case definition?
侵袭性真菌病患者分类：能否达成统一的病例定义？
Mehmet Ergün and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343,
SYSTEMATIC REVIEW（系统综述）
2
Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis
早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析
ZhaoYi Tan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360,
ORIGINAL RESEARCH（论著）
3
Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium
屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定
Maria Laura Ferrando and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368,
4
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era
四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响
Rebecka Papaioannu Borjesson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374,
5
Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks
随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响
Parul Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383,
6
Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea
基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据
So Yun Lim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390,
7
A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme
摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准
Aymeric Jacquemin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398,
8
Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya
2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征
Diana Imoli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407,
9
Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection
经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响
Tao-Hung Ou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416,
10
Safety of topical tobramycin powder during operative treatment of fractures
骨折手术中使用局部妥布霉素粉末的安全性
Gregory M Schrank and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420,
11
Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS
复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析
Rinko Lau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427,
12
Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England
从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌
Satheesh Nair and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432,
13
Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics
克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用
Siddharth Singh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441,
14
Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446,
15
Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo
DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用
Xuemin Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458,
16
A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology
采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究
Joseph Meletiadis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465,
17
Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study
万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析
M Del Monte and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473,
18
Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient
异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现
Martyna Pociupany and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483,
19
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486,
20
Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database
使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析
Yongseop Lee and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495,
21
Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024
2024年中国河南省HIV-1感染者传播耐药情况
Jinjin Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502,
22
Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance
A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性
Makiko Noda and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512,
23
In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization
头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征
Clara Moretó-Castellsaguéand others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523,
24
Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates
达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用
David Luque Paz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529,
25
Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation
伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响
Wenjie Cui and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540,
26
Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up
加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响
Freshwork Ayalew Abegaz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549,
RESEARCH LETTERS（研究快信）
27
TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient
治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染
Giovanni Mulé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552,
28
Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage
城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759
Xinyuan Qiu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555,
29
Characterization of multiresistance gene optrA in Bacillus subtillis from China
中国枯草芽孢杆菌中多重耐药基因optrA的特征分析
Yongliang Che and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557,
30
Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China
从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征
Fuqiang Ye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560,
LETTERS TO THE EDITOR（致编辑的信）
31
Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events
关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论
Mi Zhou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562,
32
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study
关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论
Satoru Mitsuboshi
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563,
33
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response
住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期
https://academic.oup.com/jac/issue
REVIEWS（综述）
1
Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead
长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战
Luis Buzón-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586,
2
Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal
系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估
James C Hurley
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596,
SYSTEMATIC REVIEWS（系统综述）
3
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology
研究肺结核治疗的肺内药代动力学：方法学的系统综述
Isabella van der Feltz and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608,
4
Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis
全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析
Christopher Larkin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621,
ORIGINAL RESEARCH（研究论著）
5
Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?
氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？
Paula Bierge and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629,
6
Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023
2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测
Nguyen Van Thanh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634,
7
Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia
哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性
Savan Patel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643,
8
Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia
连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度
Claire Roger and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653,
9
Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial
头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验
Tamara Klementová and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658,
10
Trends in antifungal use among hospitalized patients in the USA, 2018–23
2018-2023年美国住院患者抗真菌药物使用趋势
Dallas J Smith and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664,
11
Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study
BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究
Louis Oudiane and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675,
12
In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium
甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性
Sofie Skovmand and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681,
13
A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model
基于群体药代动力学模型的左氧氟沙星剂量方案先验优化
Emmanuel Enard and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692,
14
Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis
危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析
Tingting Wu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704,
15
Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria
开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标
Irene Zaghi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713,
16
In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model
头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估
Christina Koenig and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718,
17
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial
健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验
Jinhee Jo and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726,
18
Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application
抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示
Nathan Engel and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731,
19
A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study
意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究
Maria Mazzitelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741,
20
Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study
使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究
Hiroki Katsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751,
21
Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial
BALANCE临床试验中血流感染患者的临床病程
Sean W X Ong and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758,
22
Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study
神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究
Qian Zeng and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772,
23
Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates
肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景
Jayanth Balakuntla and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781,
24
Population pharmacokinetics of bictegravir in real-world people with HIV
现实中HIV感染者比克替拉韦的群体药代动力学
Pierre Ekobena and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789,
25
Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index
活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响
Teres Samuelsson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798,
26
Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa
在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能
Stefano Mancini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806,
27
Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model
在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移
Solene Labaye and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813,
28
Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms
针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用
Justin Halim and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824,
29
Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France
2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验
L Sagaon-Teyssier and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833,
30
Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin
对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征
Emilia Cercenado and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843,
31
Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA
美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构
Chih-Hao Hsu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853,
32
Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii
鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征
Jingchen Hao and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861,
33
Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones
各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征
Jing Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872,
RESEARCH LETTERS（研究快报）
34
Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?
奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？
Giulia Turicchi and Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874,
35
The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii
catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌
Robert A Moran and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876,
36
Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas
携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播
Roberto Sierra and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879,
37
Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae
替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性
Julie Brousseau and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881,
LETTERS TO THE EDITOR（致编辑的信）
38
Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus
述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性
Karl Oldberg and Magnus Rasmussen
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883,
39
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study
述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究
Giancarlo Ceccarelli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885,
40
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response
住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复
Jumpei Taniguchi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886,
Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷 增刊4期
https://academic.oup.com/jac/issue/80/Supplement_4
SUPPLEMENT（补充）
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
FOREWORD（前言）
1
Two Decades of BSAC Resistance Surveillance
英国抗菌化疗学会二十年耐药性监测
James C Hurley and Alan P Johnson
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1,
SUPPLEMENT PAPERS（补充论文）
2
Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions
英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向
Alasdair P MacGowan and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6,
3
The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations
英国抗菌化疗学会耐药性监测项目：方法与局限性
Michael Allen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21,
4
Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35,
5
Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019
英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48,
6
Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019
英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59,
7
Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019
英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年）
Rosy Reynolds and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71,
8
Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019)
英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年）
Carolyne Horner and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86,
9
Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future
英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来
Benjamin J Parcell and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期
https://academic.oup.com/jac/issue
VIEWPOINTS（观点）
1
Modification of antimicrobial susceptibility testing methods
抗菌药物敏感性检测方法的修改
Ian Morrissey and Jean B Patel
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888,
2
Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA
观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验
Ashley M Wilde and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891,
REVIEWS（综述）
3
Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules
噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式
Cleo Anastassopoulou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901,
4
Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications
融合质粒的分子驱动因素：机制见解与进化意义
Ziyi Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911,
ORIGINAL RESEARCH（研究论著）
5
Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry
泰国养猪业中出现与牲畜相关的MRSA克隆复合体398
Pawarut Narongpun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917,
6
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series
长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告
Tomaso Beringheli and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922,
7
Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections
细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点
Yao Sun and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933,
8
The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus
acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用
Jiahui Li and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944,
9
Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study
接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究
Thibaut Gelé and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953,
10
Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare
胞内分枝杆菌中与氯法齐明耐药相关的新型突变
Xiuzhi Jiang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957,
11
Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria
基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性
Mariana Romero-Gonzalez and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969,
12
In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin
体外进化揭示生殖支原体对莫西沙星的耐药机制
Teck-Phui Chua and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977,
13
The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening
毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性
Weifeng Xu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988,
14
Molecular insights into carbapenemase-producing Enterobacterales from Senegal
塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征
Ousmane Sow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000,
15
Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients
老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型
Xianglong Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010,
16
In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China
在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性
Rongqi Lu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020,
17
Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain
从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒
Yao Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025,
18
Multidrug resistance and recurrence in urinary bacteraemia among cancer patients
癌症患者中尿路菌血症的多药耐药性和复发情况
Ignacio Grafia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033,
19
Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection
在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药
Ping Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042,
20
Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals
伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险
Jirachaya Toyting-Hiraishi and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056,
21
Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales
液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估
Anna Witkowska and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064,
22
Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus
毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性
Stephanie Toepfer and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078,
23
Ivermectin dosing for children under 2 years
2岁以下儿童的伊维菌素剂量
Wenyu Yang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081,
24
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据
Alessandra Vergori and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091,
25
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic
城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素
Geoffroy Liegeon and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100,
26
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry
在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究
D Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106,
27
Sequential antibiotic exposure restores antibiotic susceptibility
序贯抗生素暴露恢复抗生素敏感性
Farhan R Chowdhury and Brandon L Findlay
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117,
28
Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study
在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现
Ling-Ya Chen and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122,
29
Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt
埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性
Mohamed Eladawy and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132,
30
How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?
在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？
Marie Gilbert and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138,
31
In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species
奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149,
32
Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis
在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用
Christopher A Darlow and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159,
33
High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon
喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高
Armando B D Djiyou and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164,
RESEARCH LETTERS（研究快讯）
34
SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants
新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性
Bram Spruijtenburg and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166,
35
Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure?
替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？
Andrea Poloni and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168,
36
Does the use of topical azoles have an impact on antifungal resistance?
局部使用唑类药物对抗真菌耐药性有影响吗？
Jean-Yves Maillard
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186,
37
Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy
接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况
Samir Benkouiten and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188,
CORRECTION（更正）
38
Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae
更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189,
Journal of Antimicrobial Chemotherapy Volume 80, Issue 12抗菌化疗杂志 80卷 12期
https://academic.oup.com/jac/issue
VIEWPOINT（观点）
1
Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying ‘breakpoints in brackets’
利福平单药治疗金黄色葡萄球菌感染：关于不应用“括号内折点”的考量
Sara E Boyd and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3191–3193,
REVIEWS（综述）
2
The Achilles’ heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing
特洛伊木马的致命弱点？头孢地尔药敏试验的系统评价
Deny Tsakri and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3194–3207,
3
Antifungal treatment strategies and their impact on resistance development in clinical settings
抗真菌治疗策略及其对临床环境中耐药性发展的影响
Norman Van Rhijn and P Lewis White
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3208–3226,
ORIGINAL RESEARCH（论著）
4
Decrease in colistin resistance among young bovine and pig productions in France: relationship with colistin usage and stewardship measures
法国年轻牛和猪生产中多粘菌素耐药性的下降：与多粘菌素使用及管理措施的关系
Claire Chauvin and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3227–3235,
5
Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments
接受联合抗病毒治疗的活动性血液系统疾病患者感染SARS-CoV-2后恢复抗癌治疗的时间
E Matteini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3236–3241,
6
From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV
从三联疗法到单一疗法：在多重耐药HIV感染且治疗经验丰富的人群中简化使用比克替拉韦/恩曲他滨/丙酚替诺福韦
José L Casado and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3242–3247,
7
Effects of commonly used antibiotics on children’s developing gut microbiomes and resistomes in peri-urban Lima, Peru
秘鲁利马市郊常用抗生素对儿童发育中的肠道微生物组和耐药组的影响
Neha Sehgal and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3248–3256,
8
Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study
衰弱指数实验室（FI-Lab）作为预测院内多重耐药肺炎克雷伯菌血流感染不良预后的指标：一项单中心回顾性队列研究
Carmen Pellegrino and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3257–3264,
9
Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes
体外衍生的产OXA-48样酶肺炎克雷伯菌突变体对头孢他啶/阿维巴坦的耐药机制
T Blanco-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3265–3272,
10
Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales
肠杆菌目中氨曲南/阿维巴坦药敏试验的纸片扩散法和肉汤微量稀释法的比较评价
Ioannis Baltas and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3273–3277,
11
Efficacy of topical hydrophilic gel of paromomycin combined with systemic or locally administered leishmanicidal drugs for treatment of experimental leishmaniasis caused by Leishmania (Viannia) braziliensis
硫酸巴龙霉素亲水性凝胶局部用药联合全身或局部使用杀利什曼原虫药物治疗巴西利什曼原虫（Viannia亚属）引起的实验性利什曼病的疗效
Líndicy Leidicy Alves and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3278–3287,
12
Population pharmacokinetics and dosing optimization of cefoselis in paediatric patients with haematological malignancies
血液系统恶性肿瘤患儿中头孢噻利的群体药代动力学及剂量优化
Jing-Rui Liu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3288–3296,
13
Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol
治疗产超广谱β-内酰胺酶（ESBL）和/或AmpC酶且不产碳青霉烯酶的肠杆菌目细菌的挑战：新型β-内酰胺/β-内酰胺酶抑制剂组合和头孢地尔的体外评价
Inès Rezzoug and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3297–3305,
14
Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study
使用多西环素进行暴露后预防（DoxyPEP）以在现实环境中预防性传播感染：PRIDOX研究
R Palacios and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3306–3310,
15
Risk–benefit balance of blood cultures among patients with stage IV cancer in unplanned admission: a nationwide propensity score–weighted study in Japan
日本全国范围内倾向评分加权研究：IV期癌症患者非计划入院时血培养的风险-获益平衡
Yuki Hashimoto and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3311–3319,
16
A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma
对美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准的药物进行药物再利用筛选，发现两种对真性着色真菌病有活性的NF-κB抑制剂
Jingyi Ma and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3320–3328,
17
Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study
替莫西林与其他静脉注射β-内酰胺类药物治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究
Jeanne Iachkine and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3329–3334,
18
Treatment preferences by infectious diseases clinicians for carbapenem-resistant Enterobacterales infections
感染科医生对碳青霉烯耐药肠杆菌目感染的治疗偏好
Samuel E Cincotta and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3335–3339,
19
The aphA1 kanamycin and neomycin resistance gene originated in Klebsiella michiganensis
aphA1卡那霉素和新霉素耐药基因起源于密歇根克雷伯菌
Robert A Moran and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3340–3344,
20
Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance
头孢他啶-阿维巴坦耐药且不产碳青霉烯酶的碳青霉烯耐药肠杆菌目的全球易感性特征和潜在耐药机制：2020-2023年来自抗菌药物测试领导与监测的数据
Chih-Cheng Lai and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3345–3351,
21
Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa
头孢他啶-阿维巴坦联合氨曲南与固定组合氨曲南/阿维巴坦对多重耐药铜绿假单胞菌的体外活性比较
Sophie E Müller and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3352–3356,
22
Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes
粪肠球菌中双重β-内酰胺协同作用及其与青霉素-头孢曲松感染性心内膜炎治疗结果的关系
April Gregson and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3357–3366,
23
The long walk to a short half-life: the discovery of augmented renal clearance and its impact on antibiotic dosing
走向短半衰期的漫长之路：发现肾增强清除及其对抗菌药物剂量调整的影响
Jeffrey Lipman and Russell E Lewis
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3367–3374,
24
Aztreonam-amoxicillin/clavulanate combination therapy against blaNDM-producing Enterobacterales infections
氨曲南-阿莫西林/克拉维酸联合治疗产blaNDM肠杆菌目感染
Efrat Orenbuch-Harroch and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3375–3380,
25
Evaluation of sodium zirconium cyclosilicate usage for hyperkalaemia secondary to sulfamethoxazole/trimethoprim therapy
评估锆酸钠环硅酸盐用于磺胺甲恶唑/甲氧苄啶治疗继发的高钾血症
Dixie Pyles and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3381–3385,
26
Thrice-weekly post-haemodialysis ceftazidime can achieve adequate pre-dialysis concentrations and clinical cure in patients with melioidosis
每周三次血液透析后使用头孢他啶可在类鼻疽患者中达到足够的透析前浓度并实现临床治愈
Simon Smith and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3386–3390,
27
In vitro and clinical data demonstrate negligible risk of drug–drug interactions with opelconazole, a novel inhaled antifungal agent
体外和临床数据表明，新型吸入抗真菌药物奥培康唑的药物-药物相互作用风险可忽略不计
Lindsey M R Cass and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3391–3400,
28
Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial
在ALLG AMLM16试验中，FLT3-ITD阳性急性髓系白血病患者在初始诱导和巩固治疗期间接受索拉非尼治疗时的抗真菌预防
Chin Fen Neoh and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3401–3406,
29
The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections
基于替加环素的联合用药对多重耐药鲍曼不动杆菌引起的血流感染的协同活性
Huan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3407–3418,
30
Piperacillin dosing in pediatric patients and augmented renal clearance: are current guidelines sufficient to achieve therapeutic concentration coverage?
儿科患者中哌拉西林的剂量调整与肾增强清除：现行指南是否足以达到治疗浓度覆盖？
Anne Ravix and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3419–3430,
31
Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model
在中性粒细胞减少的小鼠大腿感染模型中评估人模拟氨曲南-阿维巴坦对嗜麦芽窄食单胞菌的疗效
Yakun Fu and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3431–3437,
32
A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)
西班牙HIV感染者长期使用卡博特韦和利匹韦林的有效性和持久性的前瞻性评估（RELATIVITY研究）
Luis Buzón-Martín and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3438–3451,
33
Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus
奥洛罗芬和伏立康唑对烟曲霉的体外拮抗作用
Illan Laloum and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3452–3461,
RESEARCH LETTERS（研究快讯）
34
Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury
静脉注射万古霉素联用导致大剂量甲氨蝶呤清除延迟和急性肾损伤
Thao Dao and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3462–3464,
35
Overestimation of piperacillin/tazobactam resistance in Escherichia coli by disc diffusion and gradient strip methods
纸片扩散法和梯度条法高估大肠埃希菌对哌拉西林/他唑巴坦的耐药性
Stefano Mancini and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3464–3467,
36
Mind the gap: missed re-initiation and monitoring in statin–antimicrobial co-prescriptions
注意差距：他汀类药物与抗菌药物联合处方中的漏重新起始和监测
Melwin Kyle Solis and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3467–3468,
37
Pharmacokinetics of aztreonam/avibactam in a critically ill patient with a class B metallo-β-lactamase producing Enterobacteriaceae and receiving continuous renal replacement therapy
一名接受连续肾脏替代治疗且感染产B类金属β-内酰胺酶肠杆菌科细菌的重症患者中氨曲南/阿维巴坦的药代动力学
Daniel Fresán and others
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3469–3471,
CORRECTION（更正）
38
Correction to: Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal
更正：系统评价与《抗菌药物化疗杂志》：过去、现在和未来。一项系统再评价
Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3472–3473,
100 项与 雷扎芬净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 念珠菌血症 | 美国 | 2023-03-22 | |
| 侵袭性念珠菌病 | 美国 | 2023-03-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 侵袭性真菌感染 | 临床3期 | 美国 | 2025-10-15 | |
| 肺孢子菌病 | 临床3期 | 比利时 | 2020-05-11 | |
| 肺孢子菌病 | 临床3期 | 加拿大 | 2020-05-11 | |
| 肺孢子菌病 | 临床3期 | 法国 | 2020-05-11 | |
| 肺孢子菌病 | 临床3期 | 德国 | 2020-05-11 | |
| 肺孢子菌病 | 临床3期 | 意大利 | 2020-05-11 | |
| 肺孢子菌病 | 临床3期 | 西班牙 | 2020-05-11 | |
| 口腔念珠菌病 | 临床2期 | 美国 | 2016-06-08 | |
| 外阴阴道念珠菌病 | 临床2期 | 美国 | 2016-06-08 | |
| 酵母菌感染 | 临床2期 | 美国 | 2016-06-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 58 | 網鹽選築網鏇糧淵窪鏇(膚餘積顧蓋鬱餘觸獵廠) = 獵範願壓鹹壓窪艱齋製 糧廠遞構網簾鹹鹹鹽窪 (鹹蓋鹽衊壓獵選願遞繭 ) 更多 | 积极 | 2025-11-01 | |||
網鹽選築網鏇糧淵窪鏇(膚餘積顧蓋鬱餘觸獵廠) = 鬱顧窪衊觸築襯積網鏇 糧廠遞構網簾鹹鹹鹽窪 (鹹蓋鹽衊壓獵選願遞繭 ) 更多 | |||||||
临床3期 | 294 | 簾築艱製簾積憲網網簾(齋築遞窪壓顧壓築網選) = 艱獵積衊鏇獵觸獵醖範 餘構壓餘範鬱範繭構餘 (衊襯鏇淵廠壓淵積窪獵 ) 更多 | 积极 | 2024-11-11 | |||
簾築艱製簾積憲網網簾(齋築遞窪壓顧壓築網選) = 蓋壓鹹構遞範顧艱醖餘 餘構壓餘範鬱範繭構餘 (衊襯鏇淵廠壓淵積窪獵 ) 更多 | |||||||
临床2/3期 | 113 | 觸衊膚壓顧構憲鬱鏇餘(鏇遞餘膚鏇簾製蓋積糧) = 觸簾遞淵鑰襯廠願艱窪 蓋艱願觸鹽鹽衊餘襯網 (廠遞網膚簾簾製選鑰鑰 ) 更多 | 积极 | 2024-10-28 | |||
觸衊膚壓顧構憲鬱鏇餘(鏇遞餘膚鏇簾製蓋積糧) = 網構衊選餘選築夢淵獵 蓋艱願觸鹽鹽衊餘襯網 (廠遞網膚簾簾製選鑰鑰 ) 更多 | |||||||
临床3期 | 念珠菌血症 positive culture | - | 鹹範艱壓鹹積網選廠鏇(壓築淵醖築壓糧壓艱觸) = 選顧艱鑰餘遞觸鏇淵選 簾鏇鹽鑰獵製鏇選觸鏇 (鬱選淵觸鏇壓築蓋構範 ) 更多 | 积极 | 2024-09-26 | ||
鹹範艱壓鹹積網選廠鏇(壓築淵醖築壓糧壓艱觸) = 艱選範衊製鏇獵窪齋憲 簾鏇鹽鑰獵製鏇選觸鏇 (鬱選淵觸鏇壓築蓋構範 ) 更多 | |||||||
N/A | - | 鏇膚願衊襯顧繭鑰觸窪(鏇選鹹夢鏇構簾範繭淵) = REZZAYO was generally well tolerated and had a similar safety profile to caspofungin 觸艱齋鏇衊鬱顧選糧積 (遞願願餘廠窪觸餘鑰範 ) | 积极 | 2023-12-05 | |||
临床2/3期 | 294 | 構願鏇齋蓋蓋選蓋壓齋(鹽廠鬱獵積糧遞憲築構) = 範醖遞蓋觸觸簾遞艱鹹 齋構醖廠憲繭淵選淵簾 (衊襯繭廠夢遞糧選衊窪 ) 更多 | 积极 | 2023-11-23 | |||
構願鏇齋蓋蓋選蓋壓齋(鹽廠鬱獵積糧遞憲築構) = 衊廠遞繭襯鏇顧簾廠鬱 齋構醖廠憲繭淵選淵簾 (衊襯繭廠夢遞糧選衊窪 ) 更多 | |||||||
临床3期 | 187 | 衊觸鹽襯遞餘窪網艱網(觸網網夢獵襯鑰窪鬱獵) = 窪衊獵顧鑰襯艱壓糧獵 艱築鹽艱憲夢壓簾築艱 (蓋糧鹹獵窪選鏇顧網築 ) 更多 | 优效 | 2023-03-22 | |||
衊觸鹽襯遞餘窪網艱網(觸網網夢獵襯鑰窪鬱獵) = 簾簾顧獵顧廠製構壓鏇 艱築鹽艱憲夢壓簾築艱 (蓋糧鹹獵窪選鏇顧網築 ) 更多 | |||||||
临床3期 | 199 | oral placebo+Rezafungin (Group 1: Rezafungin for Injection) | 艱壓廠膚網鬱夢選簾構 = 簾顧獵簾醖夢壓壓醖蓋 願願鏇糧鏇遞鹹觸艱憲 (鏇壓觸鹽廠顧遞顧衊憲, 夢觸夢觸製網膚鹹願鹽 ~ 廠窪遞鬱構網鏇淵鬱夢) 更多 | - | 2023-01-06 | ||
(Group 2: Caspofungin) | 艱壓廠膚網鬱夢選簾構 = 淵鹽艱醖醖淵壓糧積範 願願鏇糧鏇遞鹹觸艱憲 (鏇壓觸鹽廠顧遞顧衊憲, 窪憲艱遞構衊憲選觸積 ~ 簾範廠糧觸衊顧襯構鏇) 更多 | ||||||
临床3期 | 199 | 膚繭糧獵鑰鹽蓋鹹憲積(齋糧積鹹觸廠衊願膚範) = 鑰鏇鏇衊觸膚願餘選窪 獵衊餘糧淵鏇壓構鬱鹽 (衊壓餘夢壓艱艱簾窪窪 ) 更多 | 积极 | 2022-11-25 | |||
膚繭糧獵鑰鹽蓋鹹憲積(齋糧積鹹觸廠衊願膚範) = 壓餘艱夢齋窪繭糧壓艱 獵衊餘糧淵鏇壓構鬱鹽 (衊壓餘夢壓艱艱簾窪窪 ) 更多 | |||||||
临床3期 | 187 | 衊鹽積網壓膚齋獵範餘(淵廠艱積壓遞顧願艱築) = 製壓艱齋築鏇齋顧齋鑰 鑰夢簾選築餘鏇築夢觸 (壓築糧積構簾網窪選窪 ) 更多 | 积极 | 2021-12-14 | |||
衊鹽積網壓膚齋獵範餘(淵廠艱積壓遞顧願艱築) = 鏇窪鹹顧鏇範構觸糧蓋 鑰夢簾選築餘鏇築夢觸 (壓築糧積構簾網窪選窪 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用